5,7-dihydroxy-11-ketotetranorprostanoic acid
![]() |
- $98 - $437
- Product name: 5,7-dihydroxy-11-ketotetranorprostanoic acid
- CAS: 24379-94-0
- MF: C16H28O5
- MW: 300.39
- EINECS:
- MDL Number:MFCD18428023
- Synonyms:5,7-dihydroxy-11-ketotetranorprostanoic acid;13,14-dihydro-15-keto-tetranor Prostaglandin F1α;UIZLUZTVNFGFMX-TUVASFSCSA-N;13,14-dihydro-15-keto-tetranor Prostaglandin F1.alpha.;13,14-dihydro-15-keto-tetranor Prostaglandin F1α Exclusive;Cyclopentanepropanoic acid, 3,5-dihydroxy-2-(3-oxooctyl)-, (1R,2R,3R,5S)-;13,14-dihydro-15-keto-tetranor Prostaglandin F1α;13,14-dihydro-15-keto-tetranor Prostaglandin F1α Exclusive
3 prices
Selected condition:
Brand
- Cayman Chemical
Package
- 10μg
- 25μg
- 50μg
- ManufacturerCayman Chemical
- Product number13571
- Product description13,14-dihydro-15-keto-tetranor Prostaglandin F1α ≥98%
- Packaging10μg
- Price$98
- Updated2024-03-01
- Buy
- ManufacturerCayman Chemical
- Product number13571
- Product description13,14-dihydro-15-keto-tetranor Prostaglandin F1α ≥98%
- Packaging25μg
- Price$232
- Updated2024-03-01
- Buy
- ManufacturerCayman Chemical
- Product number13571
- Product description13,14-dihydro-15-keto-tetranor Prostaglandin F1α ≥98%
- Packaging50μg
- Price$437
- Updated2024-03-01
- Buy
Manufacturer | Product number | Product description | Packaging | Price | Updated | Buy |
---|---|---|---|---|---|---|
Cayman Chemical | 13571 | 13,14-dihydro-15-keto-tetranor Prostaglandin F1α ≥98% | 10μg | $98 | 2024-03-01 | Buy |
Cayman Chemical | 13571 | 13,14-dihydro-15-keto-tetranor Prostaglandin F1α ≥98% | 25μg | $232 | 2024-03-01 | Buy |
Cayman Chemical | 13571 | 13,14-dihydro-15-keto-tetranor Prostaglandin F1α ≥98% | 50μg | $437 | 2024-03-01 | Buy |
Properties
solubility :DMF: 50 mg/ml; DMSO: 50 mg/ml; Ethanol: 50 mg/ml; PBS (pH 7.2): 1 mg/ml
Safety Information
Symbol(GHS): |
![]() |
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Signal word: | Danger | ||||||||||||||||||||||
Hazard statements: |
|
||||||||||||||||||||||
Precautionary statements: |
|